Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Methotrexate tablets
The First People's Hospital of Lianyungang
Solid Tumors
1 trial -
Mitoxantrone liposome
The First People's Hospital of Lianyungang
Relapsed or Refractory Acute Myeloid Leukemia
1 trial -
NK cell and PD-1 antibody
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
Neoadjuvant Chemotherapy (NACT)
The First People's Hospital of Lianyungang
HR+/HER2- Breast Cancer
1 trial -
Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Neoadjuvant Therapy
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial -
Neoadjuvant therapy: TCbHPy
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Nimotuzumab
The First People's Hospital of Lianyungang
Esophageal Neoplasms
1 trial -
Nimotuzumab
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
Nimotuzumab + SHR-1210
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
Nimotuzumab combined with chemoradiotherapy
The First People's Hospital of Lianyungang
Pancreatic Cancer Non-resectable
1 trial -
Nintedanib,Dextromethorphan
The First People's Hospital of Lianyungang
Idiopathic Pulmonary Fibrosis (IPF)
1 trial -
Nivolumab & Ipilimumab
The First People's Hospital of Lianyungang
Lung Cancer - Non Small Cell
1 trial -
Nivolumab Injection [Opdivo]
The First People's Hospital of Lianyungang
Neoplasms
1 trial -
OMC and pseudo-SDT
The First People's Hospital of Lianyungang
Peripheral Arterial Disease
1 trial -
ONC206
Jazz Pharmaceuticals Ireland Limited
Advanced Pheochromocytoma and Paraganglioma
1 trial -
Obinutuzumab
The First People's Hospital of Lianyungang
Large B-cell Lymphoma
1 trial -
Octacalcium phosphate
The First People's Hospital of Lianyungang
Tooth Extraction
1 trial -
Olverembatinib
The First People's Hospital of Lianyungang
Philadelphia-Positive ALL
1 trial -
Olverembatinib
The First People's Hospital of Lianyungang
Myeloproliferative Neoplasm
1 trial -
Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy
The First People's Hospital of Lianyungang
Psoriasis
1 trial -
Orelabrutinib
The First People's Hospital of Lianyungang
Primary Central Nervous System Hodgkin Lymphoma
1 trial -
Orelabrutinib
The First People's Hospital of Lianyungang
MALT Lymphoma
1 trial -
Orelabrutinib
The First People's Hospital of Lianyungang
Marginal Zone Lymphoma(MZL)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources